The Medicine Maker and NIBRT Present the Biopharma Trends Leaders’ Report 2022

Delving into the Trends of the Biopharma Industry

Since 2017, The Medicine Maker and NIBRT have collaborated on the annual Biopharma Trends report. The goal? To give readers an insight into the trends shaping the biopharmaceutical manufacturing industry. The report is usually based on a survey, but for 2022 we decided it was time for a change. After all – a great deal has changed in recent years. The COVID-19 pandemic has changed the world – and the biopharma industry. The industry has adopted new technologies and approaches to drug development – and has learned that it is possible to bring new therapies to patients in significantly reduced timelines. 

Our 2022 report explores the views of leaders from across the biopharma industry through a series of exclusive interviews. The result? Insights into the trends that will shape biopharma in the coming years – from accelerating R&D in mRNA therapeutics and pushing the frontiers in cell therapy to finding new ways to deal with the increasingly competitive environment for talent.

The Biopharma Trends Leaders’ Report 2022 features the thoughts of:

  • Maik Jornitz (G-Con)
  • Jan van de Winkel (Genmab)
  • Amélie Boulais (Sartorius)
  • James Morton & Chris Meier (Boston Consulting Group)
  • Elizabeth Topp (NIBRT)
  • Igor Splawski (CureVac)
  • Catarina Flybourg (Cytiva)
  • Fabian Gerlinghaus (Cellares)

And many more…

Sample insights

  • “The focus on vaccines and vaccine technologies cannot diminish or return to normal levels because the pandemic showed us just how utterly unprepared we were. The hope has to be that the global community looks into preparedness and protection against new, upcoming viral entities. The COVID-19 pandemic is far from over – and again a “new normal” has fallen into place.”
  • “COVID-19 was a wake-up call for the industry in so many ways and across so many areas, including supply chain fragility, manufacturing capacity limitations, and staffing constraints. Many of these strains already existed, but the pandemic exacerbated the issues. It has motivated the industry to explore new solutions in a more robust manner, with a new emphasis on business continuity planning to avoid or minimize future disruptions.”
  • “The fight against COVID-19 is continuing and this pandemic has highlighted the impact a global outbreak can have on all aspects of everyday life. The existing successful COVID-19 vaccines have shown just how effective a vaccination technology can be. Moreover, it is crucial to build on these experiences. For many of the vaccine companies, their standing and attention within the industry has been elevated and is now enabling them to act from a much stronger position.”
  • “With science advancing at unprecedented rates, it would appear that innovation is not the rate-limiting step for new product introductions. Risk tolerance/aversion, an unharmonized global regulatory system, the increase in number and diversity of health technology assessments, and pricing create challenges for new product introduction.”

View Report